This Article  • Full text  • PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (55)  • Contact me when this article is cited  Related Content  • Related article  • Similar articles in this journal  Topic Collections  • Alzheimer Disease  • Public Health  • Immunization  • Alert me on articles by topic  Social Bookmarking   What's this?

-Peptide Immunization

A Possible New Treatment for Alzheimer Disease

Dale B. Schenk, PhD; Peter Seubert, PhD; Ivan Lieberburg, MD, PhD; Jan Wallace, MD

Arch Neurol. 2000;57:934-936.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

INTRODUCTION

Research on the pathophysiological characteristics of Alzheimer disease (AD) over the past decade has been directed toward the ultimate goal of developing a disease-modifying treatment to control or prevent the disease. A report recently published in Nature¹ describes for the first time a treatment that may both prevent and treat the progression of Alzheimer disease. The treatment ironically involves immunization with the pathological -amyloid peptide itself to generate an immune response targeted against the amyloid plaques in the brain. These findings have raised a number of scientific and clinical questions that are discussed below.

ALZHEIMER DISEASE AND THE AMYLOID HYPOTHESIS

Pathologically, AD is characterized by atrophy of the cerebral cortex with loss of neurons and neuropil, the widespread appearance of senile amyloid plaques, and neurofibrillary tangles in the brain parenchyma of patients.^2-3 The relationship of these lesions to the cognitive dysfunction and . . . [Full Text of this Article]

-AMYLOID–RELATED THERAPEUTIC APPROACHES

-PEPTIDE AS A VACCINE REDUCES ALZHEIMER DISEASE–RELATED PATHOLOGY

QUESTIONS ARISING FROM THE -PEPTIDE VACCINATION FINDINGS

CLINICAL IMPLICATIONS

From Elan Pharmaceuticals, South San Francisco, Calif.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

RELATED ARTICLE

Archives of Neurology Reader's Choice: Continuing Medical Education
Arch Neurol. 2000;57(7):1089-1090.
FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Immunization With {beta}-Amyloid(1-42) Protein for Alzheimer Disease: Genomics Predicts the Response
Rosenberg
JAMA 2005;294:2352-2353.
FULL TEXT  

Immunotherapy for Alzheimer Disease: The Promise and the Problem
Rosenberg
Arch Neurol 2005;62:1506-1507.
FULL TEXT  

Risk Factors Associated With {beta}-Amyloid(1-42) Immunotherapy in Preimmunization Gene Expression Patterns of Blood Cells
O'Toole et al.
Arch Neurol 2005;62:1531-1536.
ABSTRACT | FULL TEXT  

Detangling Alzheimer's Disease
Helmuth
Sci Aging Knowl Environ 2003;2003:oa2-2.
ABSTRACT | FULL TEXT  

Alzheimer Disease: Current Concepts and Emerging Diagnostic and Therapeutic Strategies
Clark and Karlawish
ANN INTERN MED 2003;138:400-410.
ABSTRACT | FULL TEXT  

Antibodies to {beta}-Amyloid Decrease the Blood-to-Brain Transfer of {beta}-Amyloid Peptide
Pan et al.
Exp. Biol. Med. 2002;227:609-615.
ABSTRACT | FULL TEXT  

Detangling Alzheimer's Disease
Helmuth
Sci Aging Knowl Environ 2001;2001:oa2-2.
ABSTRACT | FULL TEXT  

Antibody-Mediated Phagocytosis of the Amyloid {{beta}}-Peptide in Microglia Is Differentially Modulated by C1q
Webster et al.
J. Immunol. 2001;166:7496-7503.
ABSTRACT | FULL TEXT